Literature DB >> 3258200

Depressed natural killer cell function in thermally injured adults: successful in vivo and in vitro immunomodulation and the role of endotoxin.

B S Bender1, R A Winchurch, J N Thupari, J J Proust, W H Adler, A M Munster.   

Abstract

Natural killer (NK) cells mediate host defense against infections and are regulated by interleukin 2 (IL-2) and other factors. We studied NK cell function in burn patients using a 51Cr release assay with K562 target cells. We found that peripheral blood lymphocytes from burn patients had depressed NK activity (target cell lysis = 22.0 +/- 3.1% vs 39.8 +/- 3.2% in healthy volunteers, P less than 0.001) and also a lower response to IL-2 (28.9 +/- 3.8% vs 53.2 +/- 4.3%, P less than 0.001). Thirteen burn patients were randomly assigned to receive either standard therapy or 5 days of intravenous polymyxin B in addition to standard therapy. After 2 weeks, the patients not receiving polymyxin B had a significant decline in peripheral blood NK activity (P less than 0.01) and response to IL-2 (P less than 0.05), while no decline in NK cell activity was seen in patients who received polymyxin B. Sera from burn patients was found to suppress the NK activity of lymphocytes from healthy adults by 5-75%. After using affinity chromatography to remove endotoxin, the sera from burn patients no longer suppressed NK cell activity. Circulating endotoxin appears to be involved in the suppression of NK activity in burn patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258200      PMCID: PMC1541630     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  ALTERED REACTIVITY OF SKIN HOMOGRAFTS IN SEVERE THERMAL INJURY.

Authors:  F T RAPAPORT; J M CONVERSE; L HORN; D L BALLANTYNE; J H MULHOLLAND
Journal:  Ann Surg       Date:  1964-03       Impact factor: 12.969

2.  An immunologic and nutritional evaluation of burn neutrophil function.

Authors:  E S Lennard; A B Bjornson; H G Petering; J W Alexander
Journal:  J Surg Res       Date:  1974-03       Impact factor: 2.192

3.  Herpesvirus infection in burned patients.

Authors:  F D Foley; K A Greenawald; G Nash; B A Pruitt
Journal:  N Engl J Med       Date:  1970-03-19       Impact factor: 91.245

4.  Evaluation of leukocyte chemotaxis in vitro in thermally injured patients.

Authors:  G D Warden; A D Mason; B A Pruitt
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

5.  Changes in immunoglobulin levels in severely burned patients.

Authors:  G Arturson; C F Högman; S G Johansson; J Killander
Journal:  Lancet       Date:  1969-03-15       Impact factor: 79.321

6.  Immunoglobulin levels in burned patients.

Authors:  S E Ritzmann; D L Larson; C McClung; S Abston; D Falls; A S Goldman
Journal:  Lancet       Date:  1969-06-07       Impact factor: 79.321

7.  Role of endotoxemia of intestinal origin in early death from large burns.

Authors:  P Cuevas; M Ishiyama; S Koizumi; P Woodruff; A Kaufman; J Fine
Journal:  Surg Gynecol Obstet       Date:  1974-05

8.  Altered neutrophil phagocytic function in burn patients.

Authors:  J B Grogan
Journal:  J Trauma       Date:  1976-09

9.  Alterations of serum opsonins in patients with severe thermal injury.

Authors:  A B Bjornson; J W Alexander
Journal:  J Lab Clin Med       Date:  1974-03

10.  Alterations of the immune response following severe thermal injury.

Authors:  J W Alexander; J A Moncrief
Journal:  Arch Surg       Date:  1966-07
View more
  14 in total

1.  Decrease of circulating dendritic cells in burn patients.

Authors:  A D'Arpa; A Accardo-Palumbo; G Amato; L D'Amelio; B Napoli; D Pileri; V Cataldo; R Mogavero; C Lombardo; F Conte
Journal:  Ann Burns Fire Disasters       Date:  2007-12-31

2.  Dendritic cell modification of neutrophil responses to infection after burn injury.

Authors:  Julia Bohannon; Weihua Cui; Edward Sherwood; Tracy Toliver-Kinsky
Journal:  J Immunol       Date:  2010-08-02       Impact factor: 5.422

Review 3.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

Review 4.  The systemic immune response to pediatric thermal injury.

Authors:  Racheal A Devine; Zachary Diltz; Mark W Hall; Rajan K Thakkar
Journal:  Int J Burns Trauma       Date:  2018-02-05

5.  Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice.

Authors:  Philip Lake; Jeffrey DeLeo; Franklin Cerasoli; Lennart Logdberg; Marla Weetall; Dean Handley
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 6.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

7.  Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice.

Authors:  Tracy E Toliver-Kinsky; Cheng Y Lin; David N Herndon; Edward R Sherwood
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Translocation. Incidental phenomenon or true pathology?

Authors:  A M Munster; M Smith-Meek; C Dickerson; R A Winchurch
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

9.  Phenotype and functions of natural killer cells in critically-ill septic patients.

Authors:  Jean-Marie Forel; Laurent Chiche; Guillemette Thomas; Julien Mancini; Catherine Farnarier; Céline Cognet; Christophe Guervilly; Aurélie Daumas; Frédéric Vély; François Xéridat; Eric Vivier; Laurent Papazian
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

10.  Endogenous Fms-like tyrosine kinase-3 ligand levels are not altered in mice after a severe burn and infection.

Authors:  Julia K Bohannon; Weihua Cui; Tracy Toliver-Kinsky
Journal:  BMC Immunol       Date:  2009-08-28       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.